The therapeutic efficacy of dendritic cell (DC)-based immunotherapy may be potentiated in combination with other anticancer therapies that enhance DC function by modulating immune responses and the tumor microenvironment. In this study, we investigated the efficacy of DC vaccination in combination with lenalidomide and programmed death (PD)-1 blockade in a model of murine myeloma. MOPC-315 cell lines were injected subcutaneously to establish myeloma-bearing mice and the following five test groups were established: PBS control, DCs, DCs + lenalidomide, DCs + PD-1 blockade, and DCs + lenalidomide + PD-1 blockade. The combination of DCs plus lenalidomide and PD-1 blockade more potently inhibited tumor growth compared to the other groups. This effect was associated with a reduction in immune suppressor cells (such as myeloidderived suppressor cells, M2 macrophages, and regulatory T cells) and an increase in immune effector cells [such as CD4 + and CD8 + T cells, natural killer (NK) cells, and M1 macrophages] in the spleen. Functional activities of cytotoxic T lymphocytes and NK cells were also enhanced by the triple combination. Levels of immunosuppressive cytokines, such as TGF-β and IL-10, were significantly reduced in the tumor microenvironment. These findings suggest that the combination of DCs plus lenalidomide and PD-1 blockade synergistically establishes a robust anti-myeloma immunity through a two-way mechanism, which inhibits immunosuppressive cells while activating effector cells with superior polarization of the Th1/Th2 balance in favor of the tumor immune response. This result should provide an experimental ground for incorporating check point inhibitors to existing immunotherapeutic modalities against multiple myeloma.
inTrODUcTiOn Multiple myeloma (MM) is characterized by the infiltration of clonal malignant plasma cells in the bone marrow (BM) (1, 2) . Despite advances in treating MM using novel therapies and hematopoietic stem cell transplantation, most patients experience relapses caused by immune evasion among the tumor, immune system, and tumor microenvironment (3) . Thus, new therapeutic options with the potential to overcome impaired immune surveillance are needed.
Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs) and play a key role in inducing and maintaining antitumor immunity. DCs are able to recognize, process, and present tumor antigens to generate antigen-specific cytotoxic T lymphocytes (CTLs) (4) (5) (6) (7) (8) (9) . Immune cells in myeloma patients have quantitative and functional deficiencies that contribute to myeloma-associated immune tolerance (10, 11) . By contrast, the function of DCs from patients with MM can be recovered and enhanced by ex vivo culture (12) (13) (14) . Lenalidomide is an immunomodulatory agent that targets tumor cells under immunosuppressive microenvironment (15) (16) (17) (18) (19) (20) . Our previous studies demonstrated that the combination of DC vaccination and lenalidomide synergistically enhanced antitumor immune responses in mouse tumor models (21, 22) . Programmed cell death-1 (PD-1, CD279) and its ligands [either PD-L1 (B7-H1, CD274) or PD-L2 (B7-DC, CD273)] play a fundamental role in tumor immune escape by inhibiting effector functions (23) (24) (25) (26) . The PD-1/PD-L1 blockade was recently found to effectively treat cancer by improving durable response rates and the survival profile with minimal toxicity, suggesting that blockade can be used as a cancer therapeutic agent (27) (28) (29) (30) (31) . However, recent studies reported that PD-1 blockade alone is insufficient to stimulate anti-myeloma immunity in clinical treatment (32, 33) . Thus, combination approaches with immune-checkpoint blockade and therapies that stimulate myeloma-reactive T cells can be effective tools to treat myeloma. Such as with immunomodulatory drugs, cellular therapies are currently being applied in clinical trials. Previous studies demonstrated that lenalidomide reduces the expression of PD-1 on natural killer (NK) cells, helper cells, and CTLs, and inhibits PD-L1 expression on tumor cells and myeloid-derived suppressor cells (MDSCs) in patients with MM (20, 34) . Moreover, the combination of lenalidomide and PD-1 or PDL-1 blockade increased IFN-γ expression by BM-derived effector cells in myeloma and were associated with increased apoptosis of MM cells (35) .
Thus, in this study, we investigated whether the combination of DCs plus lenalidomide and PD-1 blockade has a synergistic effect in a murine myeloma model. The results demonstrate that this combination enhanced antitumor immunity by inhibiting immunosuppressive cells and cytokines as well as activating and recovering effector cells with superior polarization toward Th1 immune response. This study provides a framework for developing a more advanced immunotherapeutic modality employing DCs, lenalidomide, and PD-1 blockade to inhibit tumor cell growth as well as restore immune functionin MM.
MaTerials anD MeThODs

Mice and Tumor cell lines
6-to 8-week-old female BALB/c (H-2 d ) mice were purchased from Orient Bio (Iksan, Republic of Korea) and maintained under specific pathogen-free conditions. All animal care, experiments, and euthanasia protocols were approved by the Chonnam National University Animal Research Committee. The murine MOPC-315 plasmacytoma cell line and the YAC-1 cell line were purchased from the American Type Culture Collection (Rockville, MD, USA). Cell lines were maintained in Dulbecco's Modified Eagle's Medium (Gibco-BRL, Grand Island, NY, USA) supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco-BRL) and 1% (w/v) penicillin/streptomycin (PS).
immunomodulatory Drug (lenalidomide) and Programmed Death-1 (anti-PD-1)
) was donated by Celgene Corporation (Summit, NJ, USA) and dissolved in dimethyl sulfoxide (DMSO) to 100 mg/mL immediately before use. For injection into mice, lenalidomide stock solutions were diluted in sterile 0.9% (v/v) normal saline to a final concentration of 10 mg/mL. The final concentration of DMSO in all experiments was <0.01% (v/v). Anti-PD-1 was purchased from BioXcell (West Lebanon, NH, USA).
generation of BM-Derived Dcs
BALB/c BM-derived immature DCs (imDCs) were generated as described previously (21, 22, 36) . Briefly, BM was harvested from the femurs and tibiae of mice and cultured in RPMI-1640 medium (Gibco-BRL) supplemented with 10% (v/v) FBS (Gibco-BRL) and 1% (w/v) PS in the presence of 20 ng/mL recombinant murine (rm) GM-CSF (R&D Systems, Minneapolis, MN, USA) and 10 ng/mL rmIL-4 (R&D Systems). On culture days 2 and 4, half of the medium was removed and replaced with fresh media containing cytokines. On day 6, imDCs were purified via positive selection with CD11c + -magnetic beads (Miltenyi Biotec, Auburn, CA, USA). Next, mature DCs were generated by further cultivation for 48 h of CD11c + DCs with 10 ng/mL rm TNF-α (R&D Systems), 10 ng/mL rmIL-1β (R&D Systems), and 10 ng/mL rmGM-CSF (R&D Systems).
generation of Dying Myeloma cell-loaded Dcs
The generation of dying myeloma cell-loaded DCs was performed as described previously (21, 22, 36) . Briefly, MOPC-315 tumor cell death was induced by γ-irradiation (100 Gy; Gammacell-1000 Elite, MDS Nordion, Canada), followed by overnight culture in RPMI-1640 without FBS, and the cells were mixed with imDCs 2 h after maturation at a 2:1 ratio (DCs:dying tumor cells).
animal Vaccination
The following five vaccination groups were established: (1) PBS control, (2) DC vaccination, (3) DC vaccination plus anti-PD-1, (4) DC vaccination plus lenalidomide injection, and (5) DC vaccination plus anti-PD-1 and lenalidomide injection. On day 0, mice were injected subcutaneously in the right flank with 5 × 10 5 MOPC-315 cells in a volume of 0.1 mL. After tumor growth, lenalidomide (0.5 mg/kg/day) was administrated orally once a day for 25 days with a 3-day break after the first 11-day dosing period. Each dose of DCs (1 × 10 6 /mouse) was injected subcutaneously into the left flank of BALB/c mice in a volume of 0.1 mL PBS on days 11, 15, 25, and 29; anti-PD-1 (250 μg/ mouse) was injected intraperitoneally in a 0.1-mL volume on the same days as DC vaccination. To assess the antitumor status of vaccinated mice, we measured the length, width, and height of each tumor every 3 to 4 days using a Vernier caliper, and we calculated tumor volume using the standard formula for calculating the volume of an ellipsoid: V = 4/3π(length × width × height/8).
Phenotypic analysis of splenocytes From Vaccinated Mice
At the indicated time points, mice were sacrificed and splenocyte phenotypes were characterized by their cell surface markers using fluorescently labeled monoclonal antibodies (mAbs) and analyzed by flow cytometry. Cells were stained with the follow- Tumor antigen-specific cTl activity of Vaccinated Mice
Tumor antigen-specific CTL activity was investigated as described previously (21, 22, 36) . Briefly, splenocytes (1 × 10 6 ) isolated from vaccinated mice 7 days after the final DC vaccination (day 36) were added to 24-well plates and restimulated with irradiated MOPC-315 cells (5 × 10 5 cells) for 5 days in RPMI-1640 (Gibco-BRL) containing 10% FBS (Gibco-BRL) and 1% PS supplemented with 20 ng/mL rmIL-2 (R&D Systems). After restimulation, we assessed the splenocytes for tumor antigen-specific CTLs using a mouse IFN-γ enzyme-linked immunospot (ELISPOT) assay (BD Bioscience). The MOPC-315 cell line and NK-sensitive YAC-1 cell line were used as target cells.
In Vitro analysis of cytokine Production in Vaccinated Mice
We determined cytokine (IFN-γ, IL-10, and TGF-β) production in vaccinated mice using the BD OptEIA™ enzyme-linked immunosorbent assay (ELISA; BD Bioscience). Supernatants from restimulated splenocytes of vaccinated mice and from single tumor cells of all vaccinated mice were assayed to measure the production of Th1-and Th2-polarizing cytokines. Each sample was analyzed in triplicate, and the mean absorbance for each set of standards and samples was calculated. 
statistical analyses
We performed statistical analyses using GraphPad Prism 4 (La Jolla, CA, USA). t-Tests, one-way analysis of variance (ANOVA), and two-way ANOVA were used as appropriate. We analyzed the survival of vaccinated mice using SigmaPlot 10.0 (Systat Software, San Jose, CA, USA). P < 0.05 was considered significant. Values are expressed as means ± SDs.
resUlTs
Dc Vaccination in combination With lenalidomide and anti-PD-1 Treatment induced a synergistic anti-Myeloma immunity effect
Our previous study (36) demonstrated that DCs maturated with GM-CSF, TNF-α, and IL-1β expressed higher levels of several molecules related to DC maturation and produced higher levels of IL-12p70 and lower levels of IL-10 compared to imDCs. In this study, we established myeloma-bearing mice to evaluate the antitumor efficacy of DC-based immunotherapies. Before treatment, we observed that high levels of PD-L1 were expressed on MOPC-315 cell lines ( Figure S1A in Supplementary Material). The established myeloma-bearing mice were initially treated with lenalidomide (0.25 or 0.5 mg/kg), PD-1 blockade (250 μg/ mouse), and dying myeloma cell-loaded DCs as a single therapy ( Figure 1A ). All single treatment groups showed significant inhibition of tumor growth compared to the PBS control group (P < 0.05; Figures S1B,C in Supplementary Material). The combination therapy of DCs plus lenalidomide and PD-1 blockade was examined in an effort to more potently inhibit tumor growth in the murine myeloma model ( Figure 1A ). All tumor-bearing mice vaccinated with PBS showed rapid tumor growth that led After tumor growth, lenalidomide (0.5 mg/kg/day) was administrated orally once a day for 25 days with a 3-day break after the first 11-day dosing period. Each dose of DCs (1 × 10 6 /mouse) was injected subcutaneously into the left flank of BALB/c mice in a volume of 0.1 mL PBS on days 11, 15, 25, and 29. Anti-PD-1 (250 μg/ mouse) was injected intraperitoneally on the same days as DC vaccination. (B) Data are presented as mean ± SEM and are representative of two independent experiments. The combination of DCs plus lenalidomide and anti-PD-1 significantly inhibited tumor growth (*P < 0.05; ***P < 0.001 on day 29) and induced a long-term systemic anti-myeloma immune response (29 days). led to a significant increase in IFN-γ-secreting splenocytes against MOPC-315 and YAC-1 cells (P < 0.05). The combination of DCs + lenalidomide + PD-1 blockade showed the highest number of IFN-γ-secreting splenocytes against MOPC-315 cells compared to the PBS control, DCs, DCs + lenalidomide, DCs + PD-1 blockade, and lenalidomide + PD-1 blockade (P < 0.05; Figure 2A ; Figure S4A in Supplementary Material). In addition, cytotoxicity by NK cells, represented by the number of IFN-γ-secreting splenocytes against YAC-1 cells, was similar in all groups that received DCs. These results indicate that the tumor inhibitory effects of DCs + lenalidomide + PD-1 blockade treatment resulted from CTL rather than NK responses. In this study, vaccination with DCs + lenalidomide + PD-1 blockade led to the production of higher levels of IFN-γ compared to the PBS control, DCs, or lenalidomide + PD-1 blockade group (Figure 2B ; Figure S4B in Supplementary Material). By contrast, TGF-β production in the DCs + lenalidomide + PD-1 blockade group was significantly lower compared to that in the PBS control, DCs, DCs + lenalidomide, or DCs + PD-1 blockade group ( Figure 2C ; Figure S4C in Supplementary Material). These results suggest that the combination of DCs + lenalidomide + PD-1 blockade induced tumor-specific CTL responses enhances through Th1 polarization. Additionally, the DCs + lenalidomide + PD-1 blockade regimen significantly increased percentages of effector CD4 + T cells ( Figure 3A ; Figure S4D in Supplementary Material), effector CD8
+ T cells (Figure 3B) , effector memory T cells ( Figure 3C ; Figure S4E in Supplementary Material), effector NK cells (Figure 3D ; Figure S4F in Supplementary Material), and M1 macrophages ( Figure 5A ; Figure S6A in Supplementary Material) compared to the other groups. To investigate the immunological mechanisms underlying the enhanced tumor-specific immune responses, we evaluated the inhibitory effects of the combination therapy (DC vaccination plus lenalidomide and PD-1 blockade) on the inhibitory cytokine production. Compared to the treatment groups, the PBS control group was significantly higher in the TGF-β production (P < 0.001). However, the production of TGF-β did not significantly differ among the treatment groups ( Figure 5C ; Figure S6C in Supplementary Material). In addition, the combination of DCs + lenalidomide + PD-1 blockade led to the production of the least IL-10 compared to other groups (P < 0.001; Figure 5D ; Figure S6D in Supplementary Material), which suggests that the combination therapy of DC vaccination plus lenalidomide and PD-1 blockade changed the tumor microenvironment toward immunostimulatory by suppressing the production of inhibitory cytokines IL-10 and TGF-β.
DiscUssiOn
Dendritic cell-based vaccines serve a promising immunotherapeutic weapon with the potential to prolong the survival of patients with incurable MM (2, 12) . Several new tools have been developed and combined to improve clinical outcomes of DC vaccination against MM (17, 18) . Recent studies have defined immune checkpoint PD-1/PD-L1 signaling as a key pathway regulating the critical balance between immune activation and tolerance (24, (37) (38) (39) (40) . The PD-1/PD-L1 pathway plays an important role in shaping the tumor-promoting, immunosuppressive microenvironment of MM. Rosenblatt et al. (41) reported that PD-L1 is highly expressed in plasma cells of MM patients but not in normal plasma cells. Our study confirmed that PD-L1 is also overexpressed on MOPC-315 cell lines (99%). Furthermore, significant PD-1 expression was observed in circulating T cells of advanced MM patients. Inhibition of the PD-1/PD-L1 signaling pathway induces an anti-MM immune response and can be a promising option for anti-myeloma therapy (42, 43) . The tumor microenvironment of MM promotes tumor cell growth and helps them escape from immune surveillance by actively suppressing anti-MM immune effector responses (1, 2). ) in the spleens of vaccinated tumor-bearing mice using flow cytometry (left panel) and compared them using quantitative bar graphs (right panel). The DCs plus lenalidomide and anti-PD-1 combination group exhibited the highest proportion of M1 macrophages and the lowest proportion of M2 macrophages compared to the other groups (*P < 0.05). Data are representative of three independent experiments. The production of (c) TGF-β and (D) IL-10 inhibitory cytokines in the tumors of tumor-bearing mice was evaluated by enzyme-linked immunosorbent assay. Compared to the treatments, PBS control led to the production of higher levels of TGF-β (***P < 0.001). However, the production of TGF-β did not differ significantly among the treatment groups. The production of IL-10 was significantly decreased in the DCs plus lenalidomide and anti-PD-1 combination therapy group compared to the other groups (***P < 0.001). Data are representative of at least three experiments. (44) . Moreover, lenalidomide plus PD-1/PD-L1 checkpoint blockade suppressed MDSCs and stroma-mediated MM growth and enhanced MM-specific cytotoxicity of immune effector cells in BM environments (35) . Our previous studies demonstrated that DC-based vaccines were safe and induced the expansion of circulating CD4 + T cells and CD8 + T cells that are specific for tumor antigens, which was synergistically enhanced by the combination of lenalidomide (21, 22, 36) . Our expectation was that the therapeutic efficacy of DC vaccination will be far more enhanced if both lenalidomide and PD-1 blockade are combined. Lenalidomide and anti-PD-1 antibody should synergistically improve the MM microenvironment, in which the host immune effector cells induced by the DC vaccination will exert anti-MM effects. This study, as expected, showed that DC vaccination combined to the lenalidomide and PD-1 blockade regiment further inhibited MM tumor growth, consequently prolonging the survival of tumor-bearing mice: the triple combination induced strong anti-myeloma CTL responses and increased the number of effector cells (CD4 + T cells, CD8 + T cells, NK cells, and M1 macrophages), while effectively discouraging suppressor cells (MDSCs, Tregs, and M2 macrophages) in the systemic immune compartment. These findings evidence the induction of systemic immune response potentially being able to eradicate disseminated diseases. DCs combined with lenalidomide and PD-1 blockade also heightened the anti-myeloma cell mediate immunity by inducing the Th1 polarization, as evidenced by the high-level production of IFN-γ, and by suppressing Th2 immune responses, as evidenced by the low-level production of IL-10 and TGF-β. Tregs, MDSCs, and M2 macrophages are major elements molding the potent immunosuppressive environment in tumor tissues. The inhibition of Treg, MDSC, and M2 macrophage accumulation in the spleen should further contribute to effective anti-myeloma cell mediate immunity in the systemic immune compartment by reciprocally activating DCs or CTLs.
Murine models of myeloma are critical tools to study the mechanisms of disease resistance, pathogenesis, and the development of new therapeutic strategies (45, 46) . This study has some limitation to interpret data due to subcutaneous injection of MOPC-315 cells for making plasmacytoma rather than BM involvement model for myeloma.
In conclusion, this study suggests that lenalidomide plus PD-1 blockade treatment synergistically enhances the efficacy of DC vaccination in a murine myeloma model by inhibiting the generation of immunosuppressive cells and the Th2 immune response and enhancing effector cells and the Th1 immune responses. We hereby propose a framework for a more efficacious DC-based vaccination strategy against MM with the combination of immunomodulatory drug lenalidomide and anti-PD-1 antibody.
eThics sTaTeMenT
All animal care, experiments, and euthanasia protocols were approved by the Chonnam National University Animal Research Committee. (B) IFN-γ and (c) TGF-β production in the splenocytes of vaccinated mice was evaluated by enzyme-linked immunosorbent assay. The combination of DCs plus lenalidomide and anti-PD-1 led to the production of higher levels of IFN-γ compared to treatment with lenalidomide plus anti-PD-1 (***P < 0.001). The production of TGF-β did not differ significantly between the two groups. Data are shown as the mean (pg/mL) ± SD of triplicate cultures from three independent experiments. We measured proportions of (D) CD4 + T cells, (e) memory T cells, and (F) NK cells using flow cytometry (left panel) and compared them using quantitative bar graphs (right panel). The results revealed significant increases in CD4
+ T cells and memory T cells in the DCs plus lenalidomide and anti-PD-1 group compared to the lenalidomide plus anti-PD-1 group (*P < 0.05; ***P < 0.001). Percentages of NK cells did not differ significantly between the two groups. Data are representative of at least three experiments. FigUre s6 | Enhanced M1 and impaired M2 macrophage polarization and reduced inhibitory cytokine production by a combination of dendritic cells (DCs) plus lenalidomide and anti-PD-1. We measured proportions of (a) M1 macrophages (CD11b + F4/80 + CD206 − ) and (B) M2 macrophages (CD11b + F4/80 + CD206 + ) in the spleens of vaccinated tumor-bearing mice using flow cytometry (left panel) and compared them using quantitative bar graphs (right panel). The DCs plus lenalidomide and anti-PD-1 combination group showed significantly increased proportions of M1 macrophages compared to the lenalidomide plus anti-PD-1 group (*P < 0.05). Percentages of M2 macrophages did not differ significantly between the two groups. Data are representative of at least three experiments. The production of (c) TGF-β and (D) IL-10 inhibitory cytokines in the tumors of tumor-bearing mice was evaluated by enzyme-linked immunosorbent assay. The production of IL-10 was significantly decreased in the DCs plus lenalidomide and anti-PD-1 combination therapy group compared to the lenalidomide plus anti-PD-1 group (***P < 0.001). The production of TGF-β did not differ significantly between the two groups. Data are representative of at least three experiments.
